Sergio Cifuentes, Medical Oncologist at Las Américas Auna Clinic, shared a post on X:
“Not all HR+/HER2-low mBC is the same. Time to progression on 1L ET + CDK4/6 and baseline disease burden matter.
In the DESTINY Breast06 subgroup analysis, trastuzumab deruxtecan (T-DXd) improved PFS across all groups: early or late progression, primary or secondary endocrine resistance, high tumor burden or visceral disease.
Clear message: the benefit is consistent, even in more aggressive biology.
HER2-low is no longer just a biomarker. It’s a treatment decision.”
Title: Trastuzumab deruxtecan in hormone receptor–positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
Authors: G. Curigliano, X. Hu, R. Dent, K. Yonemori, C. H. Barrios, J.-Y. Pierga, F. Puglisi, J.-M. Ferrero, K. H. Jung, N. A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia.
More posts featuring Sergio Cifuentes on OncoDaily.
